Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies. The company also engages in licensing activities for proprietary products which utilize unique intranasal formulation delivery technology, discovery of future seeds, and business promotion activities; and development of artificial seed production for Japanese eels. In addition, it operates hotels accommodations facilities under the Villa Amafuru Oka and HOTEL Freesia names; and develops and operates geothermal and hot spring thermal power plants. Shin Nippon Biomedical Laboratories, Ltd. was founded in 1957 and is headquartered in Kagoshima, Japan.
Frequently asked questions
What sector does Shin Nippon Biomedical Laboratories Ltd (2395) operate in?
Shin Nippon Biomedical Laboratories Ltd belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is Shin Nippon Biomedical Laboratories Ltd (2395) current stock price?
As of the latest data, Shin Nippon Biomedical Laboratories Ltd stock price is ¥1,347, with a previous close of ¥1,349. Shin Nippon Biomedical Laboratories Ltd lost -¥2 in the last trading session, representing a -0.15% loss.
What is Shin Nippon Biomedical Laboratories Ltd (2395) current market capitalization?
Shin Nippon Biomedical Laboratories Ltd market cap is approximately 56.08 billion.
What is Shin Nippon Biomedical Laboratories Ltd (2395) Earnings Per Share (EPS)?
The trailing EPS is ¥110, and the forward EPS is ¥106.
What is Shin Nippon Biomedical Laboratories Ltd (2395) Price-to-Earnings (P/E) ratio?
Shin Nippon Biomedical Laboratories Ltd current P/E ratio is 12.28, with a forward P/E of 12.68.
What is Shin Nippon Biomedical Laboratories Ltd (2395) EBITDA?
Shin Nippon Biomedical Laboratories Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 1.31 billion.
Does Shin Nippon Biomedical Laboratories Ltd (2395) pay dividends?
Yes. Shin Nippon Biomedical Laboratories Ltd pays semiannual dividends with an annualized yield of 4.45% and an estimated annual payout of ¥60 per share.
When is the next ex-dividend date for Shin Nippon Biomedical Laboratories Ltd (2395)?
The next ex-dividend date is scheduled for September 30, 2026.
What is Shin Nippon Biomedical Laboratories Ltd (2395) beta (volatility) score?
Shin Nippon Biomedical Laboratories Ltd has a beta of -0.207, indicating lower volatility than the overall market.
